Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cardiol Therapeutics Inc (CRDL.TO)

Cardiol Therapeutics Inc (CRDL.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Cardiol Therapeutics Inc 2265 Upper Middle Road East Suite 602 Oakville ON L6H 0G5 CAN

https://www.cardiolrx.com P: 289-910-0850

Sector:

Medical

Description:

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Key Statistics

Overview:

Market Capitalization, $K 228,944
Shares Outstanding, K 111,680
% of Institutional Shareholders 0.08%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -33,819 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -7,213 K

Growth:

1-Year Return 68.94%
3-Year Return 150.00%
5-Year Return -51.65%
5-Year Revenue Growth 0.00%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.39
EPS Growth vs. Prev Year -23.53%
Dividend Payout Ratio 0.00%

CRDL.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -158.75%
Return-on-Assets % -121.91%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Book 12.81
Book Value/Share 0.16
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.